US equities |
NVDA $241.81 ▲+1.22% SPCX $173.94 ▲+1.67% MU $1,065.08 ▲+0.11% AMD $656.65 ▲+3.94% MRVL $292.06 ▲+7.67% SNDK $1,674.45 ▼-1.74% AVGO $378.65 ▲+4.45% TSLA $380.23 ▲+0.39%
FinancialContent

Articles published by Neumora Therapeutics, Inc.

News headline image
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Host Virtual R&D Day on October 27
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in September
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Announces Leadership Transition
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
News headline image
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA